Country: Canada
Language: English
Source: Health Canada
BELIMUMAB
GLAXOSMITHKLINE INC
L04AG04
BELIMUMAB
400MG
POWDER FOR SOLUTION
BELIMUMAB 400MG
INTRAVENOUS
20ML
Prescription
IMMUNOSUPPRESSIVE AGENTS
Active ingredient group (AIG) number: 0152941001; AHFS:
APPROVED
2011-07-06
_ _ _ _ _BENLYSTA, Belimumab _ _Page 1 of 66_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr BENLYSTA Belimumab for injection 120 mg in 5 mL vial lyophilized powder for intravenous infusion 400 mg in 20 mL vial lyophilized powder for intravenous infusion Belimumab injection 200 mg in 1 mL for subcutaneous injection Selective Immunosuppressant GlaxoSmithKline Inc. 100 Milverton Drive Suite 800 Mississauga, Ontario L5R 4H1 Date of Initial Authorization: July 06, 2011 Date of Revision: March 6, 2024 Submission Control Number: 279901 _©_ _2024 GSK group of companies or its licensor _ _Trademarks are owned by or licensed to the GSK group of companies _ _ _ _ _ _BENLYSTA, Belimumab _ _Page 2 of 66_ RECENT MAJOR LABEL CHANGES SECTION DATE 7 WARNINGS AND PRECAUTIONS 10/2023 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 05/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................... 4 1.2 Geriatrics ................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.1 Dosing Considerations ............................................................... 5 4.2 Recommended Dose and Dosage Adjustment .......................... 5 Read the complete document